223 related articles for article (PubMed ID: 15646075)
1. "Solving the puzzle" of current HAART: what key strategic trials are needed?
Carosi G; Torti C
New Microbiol; 2004 Apr; 27(2 Suppl 1):127-30. PubMed ID: 15646075
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. The future of antiretroviral therapy: challenges and needs.
Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
[TBL] [Abstract][Full Text] [Related]
4. HIV infection and advanced age emerging epidemiological, clinical, and management issues.
Manfredi R
Ageing Res Rev; 2004 Jan; 3(1):31-54. PubMed ID: 15164725
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
Lagnese M; Daar ES
Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
[TBL] [Abstract][Full Text] [Related]
6. New drugs for old.
Winston A; Stebbing J
J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
[TBL] [Abstract][Full Text] [Related]
7. [Salvage therapy in HIV infection].
Salzberger B
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies for highly treatment-experienced HIV-infected patients.
Luber AD
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):815-23. PubMed ID: 16207173
[TBL] [Abstract][Full Text] [Related]
9. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.
Hamers RL; Derdelinckx I; van Vugt M; Stevens W; Rinke de Wit TF; Schuurman R;
Antivir Ther; 2008; 13(5):625-39. PubMed ID: 18771046
[TBL] [Abstract][Full Text] [Related]
10. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
11. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
12. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Sproat M; Pozniak AL; Peeters M; Winters B; Hoetelmans R; Graham NM; Gazzard BG
Antivir Ther; 2005; 10(2):357-61. PubMed ID: 15865231
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
14. Treatment interruptions in HIV-infected subjects.
Bongiovanni M; Casana M; Tincati C; d'Arminio Monforte A
J Antimicrob Chemother; 2006 Sep; 58(3):502-5. PubMed ID: 16816398
[TBL] [Abstract][Full Text] [Related]
15. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
Grant PM; Zolopa AR
Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
[TBL] [Abstract][Full Text] [Related]
16. A virological perspective on resistance in highly treatment-experienced patients.
Geretti AM
J HIV Ther; 2002 Nov; 7(4):97-101. PubMed ID: 12733608
[TBL] [Abstract][Full Text] [Related]
17. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
[No Abstract] [Full Text] [Related]
18. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
19. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
20. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
